Healios Expects To Take Regenerative Medicine Lead in 2018
This article was originally published in PharmAsia News
Executive Summary
Healios President Tadashisa Kagimoto said he expects to move a macular-degeneration regenerative-medicine treatment out of early-stage clinical trials to its joint venture with Dainippon Sumitomo Pharma to take it through the next stage of trials.